Biotechnology
Biopharmaceutical
Pharmaceutical

AMAG Pharmaceuticals

$11.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AMAG and other stocks, options, ETFs, and crypto commission-free!

About AMAG

AMAG Pharmaceuticals, Inc. Common Stock, also called AMAG Pharmaceuticals, is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Read More The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Employees
467
Headquarters
Waltham, Massachusetts
Founded
1981
Market Cap
386.47M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.84M
High Today
$11.64
Low Today
$11.27
Open Price
$11.51
Volume
1.19M
52 Week High
$25.20
52 Week Low
$6.81

Collections

Biotechnology
Biopharmaceutical
Pharmaceutical
Manufacturing
Health
Technology
Therapy
US

AMAG News

ReutersAug 14

Edited Transcript of AMAG earnings conference call or presentation 7-Aug-19 12:00pm GMT

94

AMAG Earnings

-$1.59
-$1.03
-$0.46
$0.10
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.49 per share
Actual
-$1.14 per share

More AMAG News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.